Pain Relief Recall: Missing Safety Info Sparks Concern

A precautionary recall has been issued for specific batches of Napralief 250mg Gastro-Resistant Tablets due to significant omissions in their patient information leaflets and outer packaging. These omissions pertain to critical safety and dosage information, potentially leading to patient harm.

The affected batches, identified by numbers B51496, B51497, and B51102, are missing essential instructions. These include the maximum daily dosage of three tablets, initial treatment dosing schedules, and guidance on seeking eye examinations for visual disturbances. Warnings about serious allergic reactions and advice for medical tests are also absent.

Furthermore, information concerning heart problems, autoimmune diseases, and potential serious skin reactions was not fully provided. These gaps mean patients may not receive the complete guidance necessary for safe usage. The MHRA Chief Safety Officer emphasized that while unintentional minor dosing errors are usually harmless, complete information is vital for correct use.

Patients are advised to continue using the medication according to the correct dosage instructions: two tablets on the first day, followed by one tablet 6-8 hours later. For the subsequent two days, one tablet every 6-8 hours if needed, not exceeding three days of use. Any adverse effects or questions should be discussed with a healthcare professional. The MHRA has directed healthcare professionals to halt the supply of the affected batches.